BNF 84 (British National Formulary) September 2022-March 2023: 84: September 2022 - March 2023

Product Information

Please note that co-trimoxazole currently has its own entry in print that does not include the interactions for trimethoprim. As stated above, it is essential to refer to both drugs (trimethoprim and sulfamethoxazole, under sulfonamides) to find all relevant interactions for this drug. This inconsistency will be corrected in the upcoming September editions, BNF 78 and BNF for Children 2019-2020. Digital products including MedicinesComplete and the BNF app have been corrected for the June monthly update. The vaccines class monograph has also been reviewed and updated. Information that is common to all vaccines can be found in the Vaccines, general class monograph. A new class monograph Vaccines, live contains information that is only relevant to live vaccines. Some monographs may have additional information that is specific to the individual vaccine. In such cases, information from the class monograph(s) and the individual monograph need to be considered together. The British National Formulary (BNF) is a book that is published twice a year in March and September. Compiled with the advice of clinical experts, its an essential reference providing up to date guidance on the prescribing, dispensing and administration of medicines. British National Formulary (BNF) Product Details: Joint Formulary Committee (2021) 'Paracetamol', in British National Formulary. Available at: https://www-medicinescomplete-com.apollo.worc.ac.uk/#/content/bnf/_970446495(Accessed: 21July2022). Adrenaline/epinephrine: recall of Emerade® 500 micrograms and Emerade® 300 micrograms auto-injectors, due to the potential for device failure [National Patient Safety Alert advice]

For each vaccine monograph, the Drug action section includes a short summary of the vaccine type. Detailed information on the vaccine’s mechanism of action can be found in the corresponding Treatment summaries. The classifications, which are used to group similar vaccines, have also been updated. Specialist drug monographs: inclusion of the words “Specialist drug” alongside the monograph title to identify drugs used within specialist settings (such as drugs used for malignancy, and those given via intravitreal injection). These monographs continue to include information to support patient safety and non-specialist patient care (such as important safety information, interactions, side-effects, and contra-indications) but no longer include information which is within the remit of specialist care (such as doses, and directions for administration). The interactions are displaying correctly when the interactions information is accessed directly via links from the Interactions section of the co-drug monographs in BNF and BNF for Children. Over the last year, we have undertaken research to understand how we could ensure that specialist drug content in BNF Publications is aligned with the stated scope within the preface, and with the primary use case of the BNF. Analytics around the use of BNF Publications’ content confirmed that specialist drug content is accessed much less frequently than drug content for non-specialist use. User research supported the analytics, and showed that those users who did access specialist content were most commonly looking at safety information, such as contra-indications, interactions, and side-effects.

Need more help?

Pre-treatment screening advice on genetic testing for aminoglycoside exposure posing risk to hearing Physical Examination Procedures for Advanced Practitioners and Non-Medical Prescribers - 2nd ed. (2015) Vaccine monographs in the BNF and BNF for Children have been updated to more clearly identify whether a vaccine is live or not. Ideal for use by Pharmacists, Chemists, Nurses and Doctors within Hospitals, Nursing Homes, Pharmacies and Hospices and the ideal reference tool for all Care and support staff. See also:

Pharmaceutical Preformulation and Formulation: a Practical Guide from Candidate Drug Selection to Commercial Dosage Form - 2nd ed. (2009)Based on the primary use case of BNF Publications, supporting non-specialist clinical practice, the preface of the BNF sets out that less detail is given for specialist areas such as malignant disease. However, there has been no consistent style used within BNF monographs to highlight to users that a drug is used in these specialist areas. For some vaccines, such as the influenza vaccines, live and inactivated preparations are available, so information has been separated into two monographs. Users should ensure they are referring to the correct monograph when looking for information; to navigate between related monographs, use the cross-reference in the Drug action section. We may be able to source and supply a paper copy in exceptional circumstances, from surplus BNFs distributed to other parts of the NHS. Please register your interest in receiving a copy via the online form at: https://www.snapsurveys.com/wh/s.asp?k=153553886772 From June 2023, BNF Publications will be more clearly and consistently identifying specialist drug monographs within content, by including the words “Specialist drug” alongside the monograph title. This feature will be applied to existing monographs, and to monographs moving forward, that are used within specialist settings (such as drugs used for malignancy, and those given via intravitreal injection). These “specialist drug” monographs will contain less detail than a regular monograph within BNF Publications. A “specialist drug” monograph will continue to include information to support patient safety and non-specialist patient care (such as important safety information, interactions, side-effects, and contra-indications), but it will not contain information which is within the remit of specialist care (such as doses, and directions for administration).

Paper copies were historically distributed yearly, each October. The digital versions will take over from this October 2018.Biologics, Biosimilars and Biobetters: An Introduction for Pharmacists, Physicians and other Health Practitioners(2021) With the latest update, you now have access to the new features on the BNF app, providing you with an improved experience. Ibrutinib (Imbruvica®): new risk minimisation measures, including dose modification recommendations, due to the increased risk for serious cardiac events Livtencity® [maribavir] for cytomegalovirus disease in recipients of haematopoietic stem cell transplant or solid organ transplant Our opening hours are from 9 am till 5 pm Monday to Thursday and 8:30 am till 4:30 pm on Fridays. You may also like…

Blood Results in Clinical Practice: A Practical Guide to Interpreting Blood Test Results - 2nd ed. (2019) As noted in the British National Formulary (BNF) the recommended dosage for children under 12 is...(Joint Formulary Committee, 2021)." A British National Formulary (BNF) is a medical and pharmaceutical publication that contains information and advice on prescribing and pharmacology, along with specific facts and details about all medicines available on the NHS. Pholcodine-containing cough and cold medicines: withdrawal from UK market as a precautionary measureManagement of iron deficiency anaemia, including update to oral iron dosing and monitoring based on British Society of Gastroenterology guidelines The cover image preview of BNF 84 (British National Formulary) September 2022 – March 2023 PDF Looks Something like this: The results of this research have enabled us to critically review the information that should be included within specialist drug monographs. “Specialist drug” monographs will contain less detail than a regular monograph within BNF Publications, in a consistent format. A “specialist” monograph will continue to include information to support patient safety and non-specialist patient care (such as important safety information, interactions, side-effects, and contra-indications), but it will not contain information which is within the remit of specialist care (such as doses, and directions for administration). The current level of additional prescribing information has been retained for drug monographs that have a mix of specialist and non-specialist uses (such as methotrexate that is used for both malignancy and rheumatological conditions). Author (Year of publication) 'Title of chapter/section', in Title of reference source.Available at: URL (Accessed: date).